Veraxa Biotech AG has received scientific advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed nonclinical development plan for its most advanced development program based on its proprietary BiTAC-TCE (bi-targeted tumor-associated cytotoxicity T-cell engager) technology.